Top Markets
#1 龙虾 (Lobster) 龙虾 (Lobster) +111.56%
#2 Lisk Lisk +79.88%
#3 Not in Employment, Education, or Training Not in Employment, Education, or Training +32.86%
#4 Tokenlon Tokenlon +28.91%
#5 Nockchain Nockchain +28.07%
#6 Alchemist AI Alchemist AI +25.95%
#7 earnAUSD earnAUSD +24.75%
#8 Illuvium Illuvium +22.65%
#9 Renzo Renzo +21.31%
#10 Akedo Akedo +18.08%
Coin of the day
龙虾 (Lobster) 龙虾 (Lobster)
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
MultiCell Technologies, Inc. MultiCell Technologies, Inc.

MultiCell Technologies, Inc.

MCET
Rang in Aktien #41009
MultiCell Technologies, Inc. (MCET) operates as a biopharmaceutical firm,... MultiCell Technologies, Inc. (MCET) operates as a biopharmaceutical firm, primarily focused on the creation of innovative therapeutic agents and research tools. Their efforts are directed towards addressing a range of medical challenges, including neurological conditions, liver ailments, various types of cancer, and applications within interventional cardiology and peripheral vascular health. The company's product pipeline features several key developments: MCT-125: This investigational therapy is currently in Phase II clinical trials, targeting the primary fatigue commonly associated with multiple sclerosis. MCT-465: A preclinical-stage synthetic double-stranded RNA (dsRNA) candidate, designed to act as a powerful immune enhancer for the treatment of solid tumor malignancies. MCT-485: Another dsRNA therapeutic, still in the discovery phase, which demonstrates tumor cytolytic (cell-destroying) properties, intended for use against diverse cancers. Beyond drug candidates, MultiCell Technologies is also progressing the Ideal BioStent, an innovative bioabsorbable stent specifically engineered for use in interventional cardiology and peripheral vessel procedures. The organization maintains licensing agreements with prominent entities such as Corning Incorporated and Pfizer Inc. Established in 1962, the company was previously known as Exten Industries, Inc. before officially changing its name to MultiCell Technologies, Inc. in April 2004. Its corporate headquarters are situated in Woonsocket, Rhode Island.
Aktienkurs
$0.00001
Zuletzt synchronisiert: 2026-09-10
Marktkapitalisierung
$50.01K
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel MultiCell Technologies, Inc. (MCET)

Kategorie

Healthcare
EPS für MultiCell Technologies, Inc. (MCET)
EPS zum August 2015 TTM: $0.00
Laut den aktuellen Finanzberichten und dem Aktienkurs von MultiCell Technologies, Inc. beträgt das aktuelle EPS des Unternehmens (TTM) $0.00. Am Ende des Jahres 2013 betrug das EPS $0.00 gleich wie dem EPS von 2026, das 0 betrug.
EPS-Verlauf von MultiCell Technologies, Inc. von 2013 bis 2026
EPS am Ende jedes Jahres
Jahr EPS ändert
2026 (TTM) 0.00 -83.33%
2014 0.00 -83.33%
2013 0.00 0.00%
EPS für ähnliche Unternehmen oder Wettbewerber
Unternehmen EPS EPS-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 692,700.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 1,109,500.00%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $-7.98 -319,300.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $-5.29 -211,700.00%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH